Protozoa Destroying Or Inhibiting Patents (Class 514/4.4)
  • Patent number: 9433671
    Abstract: Multilayer films comprise polypeptide epitopes from Plasmodium falciparum, specifically a circumsporozoite T1, B or T* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a Plasmodium protozoan.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: September 6, 2016
    Assignee: ARTIFICIAL CELL TECHNOLOGIES, INC.
    Inventor: Thomas J. Powell
  • Publication number: 20150104492
    Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventors: Alison McDermott, Marialuisa Mangoni
  • Patent number: 8883717
    Abstract: Multilayer films comprised of polypeptide epitopes and a toll-like receptor ligand are described. The multilayer films are capable of eliciting an immune response in a host upon administration to the host. The multilayer films can include at least one designed peptide that includes one or more polypeptide epitopes from a virus, bacteria, fungus or parasite.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: November 11, 2014
    Assignee: Artificial Cell Technologies, Inc.
    Inventors: Thomas J. Powell, James Gorham Boyd
  • Publication number: 20140287990
    Abstract: The present invention relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to treat and/or prevent two or more conditions in a mammalian cell. The invention also relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to concurrently treat and/or prevent two or more conditions in a patient such as HIV, cancer, malaria and inappropriate angiogenesis.
    Type: Application
    Filed: December 2, 2013
    Publication date: September 25, 2014
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Tapas Das Gupta, Ananda Chakrabarty
  • Publication number: 20140255299
    Abstract: In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
    Type: Application
    Filed: August 24, 2012
    Publication date: September 11, 2014
    Applicant: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: Annette Khaled, Rebecca Boohaker, Michael Lee, Jesus Perez Figueroa
  • Publication number: 20140235531
    Abstract: The present invention is directed to the peptides WKWLKKWIK, WRKFWKYLK, and RRWRVIVKW and use of said peptides as therapeutic agents for the prophylaxis and/or treatment of infections, in particular bacterial and/or fungal infections and diseases caused by bacterial and/or fungal infections.
    Type: Application
    Filed: October 10, 2012
    Publication date: August 21, 2014
    Inventor: Dorian Bevec
  • Publication number: 20140228279
    Abstract: The disclosure provides cationic peptidopolysaccharides of Formula I: which has a bacterial peptidoglycan-mimetic structure, and shows outstanding broad spectrum activities against clinically significant bacteria and fungi. The structural affinity of these compounds with microbial cell wall constituents promotes its passage to the cytoplasmic membrane resulting in excellent antimicrobial activity and record high selectivity.
    Type: Application
    Filed: October 3, 2012
    Publication date: August 14, 2014
    Applicant: Nanyang Technological University
    Inventors: Bee Eng Mary Chan, Peng Li
  • Publication number: 20140221276
    Abstract: A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.
    Type: Application
    Filed: April 18, 2014
    Publication date: August 7, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Roger Linington, Laura Sanchez
  • Publication number: 20140219971
    Abstract: The present invention relates to the production of malaria transmission blocking vaccines in single-celled green algae, particularly algae of the genus Chlamydomonas, e.g., Chlamydomonas reinhardtii; the immunogenic Plasmodium polypeptides produced and compositions comprising them; and methods for preventing, ameliorating, reducing, delaying, treating and blocking the transmission of malaria by administration of immunogenic Plasmodium polypeptides produced in an algal host cell.
    Type: Application
    Filed: May 1, 2012
    Publication date: August 7, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Stephen P. Mayfield, James A. Gregory, Carla S. Jones, Michael J. Hannon
  • Publication number: 20140220086
    Abstract: Antimicrobial compositions including a cell penetrating peptide (CPP) having the amino acid sequence Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Gly-Tyr-Ala-Arg-Val-Arg-Arg-Arg-Gly-Pro-Arg-Arg (SEQ ID NO:1) or variant thereof are disclosed. The CPP, which itself has antimicrobial properties, can be advantageously combined with or conjugated to a cargo to increase the delivery, efficacy, or combinations thereof, of the cargo into cells. In preferred embodiments, the CPP is combined with or conjugated to a functional nucleic acid, such as an external guide sequence (EGS) which can target and reduce expression of essential microbial genes or genes than impart resistance to antimicrobial drugs. Methods of using the compositions alone or in combination with traditional antimicrobial drugs to treat infections are also disclosed.
    Type: Application
    Filed: September 21, 2012
    Publication date: August 7, 2014
    Inventors: Sidney Altman, Alfred Bothwell, Choukri Mamoum
  • Publication number: 20140194345
    Abstract: The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders.
    Type: Application
    Filed: December 3, 2013
    Publication date: July 10, 2014
    Inventors: Aaron J. Peoples, Dallas Hughes, Losee Lucy Ling, William Millett, Anthony Nitti, Amy Spoering, Victoria Alexandra Steadman, Jean-Yves Christophe Chiva, Linos Lazarides, Michael Kenyon Jones, Karine Gaelle Poullenec, Kim Lewis
  • Publication number: 20140155318
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Application
    Filed: September 3, 2013
    Publication date: June 5, 2014
    Applicant: Tel Hashomer Medical Research, Infrastructure and Services Ltd.
    Inventor: Amir ZLOTKIN
  • Patent number: 8691943
    Abstract: NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: April 8, 2014
    Assignee: The United States of America, as represented by the Secretary of Agriculture
    Inventors: Hyun Soon Lillehoj, Sung Hyen Lee, Yeong ho Hong
  • Publication number: 20140093531
    Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.
    Type: Application
    Filed: December 5, 2013
    Publication date: April 3, 2014
    Applicants: Fundacao Oswaldo Cruz (FIOCRUZ), The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Jesus G. Valenzuela, Jose M.C. Ribeiro, Aldina Barral, Manoel Netto, Claudia I. Brodskyn, Regis Gomes
  • Publication number: 20140080753
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: November 12, 2013
    Publication date: March 20, 2014
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Kevin D. SHENK, Francesco PARLATI, Han-jie ZHOU, Catherine SYLVAIN, Mark S. SMYTH, Mark K. BENNETT, Guy J. LAIDIG
  • Publication number: 20140056906
    Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.
    Type: Application
    Filed: October 8, 2013
    Publication date: February 27, 2014
    Applicant: INCYTE CORPORATION
    Inventors: Henry Yue, Monique G. Yao, Ameena R. Gandhi, Mariah R. Baughn, Anita Swarnakar, Narinder Walia, Madhusudan M. Sanjanwala, Michael Thorton, Vicki S. Elliott, Yan Lu, Kimberly J. Gietzen, Neil Burford, Li Ding, April J. A. Hafalia, Y. Tom Tang, Olga Bandman, Bridget A. Warren, Cynthia D. Honchell, Dyung Aina M. Lu, Kavitha Thangaveln, Sally Lee, Yuming Xu, Junming Yang, Preeti G. Lal, Bao Tran, Craig H. Ison, Brendan M. Duggan, Stephanie Sapperstein
  • Patent number: 8652457
    Abstract: The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 18, 2014
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Jordan Marshall Sand, Mark Eric Cook
  • Publication number: 20140017248
    Abstract: The present disclosure is directed to interleukin-10 (IL-10) peptides and isolated antibodies that specifically bind to the IL-10 peptides. The IL-10 peptides and the isolated antibodies may be administered alone or as an animal feed additive to treat gastrointestinal protozoan infection in animals.
    Type: Application
    Filed: July 13, 2012
    Publication date: January 16, 2014
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Jordan Marshall Sand, Mark Eric Cook
  • Patent number: 8623816
    Abstract: The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by P. falciparum. The invention provides isolated peptides that are variants, derivatives or structural equivalents of cupredoxins or cytochrome c, and compositions comprising cupredoxins and/or cytochrome c, or variants, derivatives or structural equivalents thereof, that are useful for treating or preventing malaria infection in mammals. Further, the invention provides methods to treat mammalian patients to prevent or inhibit the growth of malarial infection in mammals. The invention also provides methods to prevent the growth of malaria infection in insect vectors.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: January 7, 2014
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Ananda Chakrabarty, Tapas Das Gupta, Tohru Yamada, Anita Chaudhari, Arsenio Fialho, Chang Soo Hong
  • Publication number: 20130315984
    Abstract: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides.
    Type: Application
    Filed: May 31, 2013
    Publication date: November 28, 2013
    Applicant: University of Georgia Studies Research Center
    Inventor: University of Georgia Studies Research Center
  • Publication number: 20130303439
    Abstract: The invention related to chimeric peptides including a penetrating peptide and a binding domain of PP2A catalytic subunit to caspase-9 which have pro-apoptotic activity. These chimeric peptides may be used for the treatment of hyperproliferative disorders.
    Type: Application
    Filed: September 30, 2011
    Publication date: November 14, 2013
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), INSTITUT CURIE
    Inventors: Angelita Rebollo Garcia, Didier Decaudin, Fariba Nemati
  • Publication number: 20130280297
    Abstract: The invention provides immunomodulatory proteins, e.g., useful to prevent, inhibit or treat microbial infection.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 24, 2013
    Inventors: Lori Neal, Laura Knoll, Erik Settles, Lindsey Anne Moser
  • Publication number: 20130217616
    Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
    Type: Application
    Filed: March 4, 2011
    Publication date: August 22, 2013
    Inventors: Peter Garred, Tina Hummelshøj Glue, Mikkel-Ole Skjødt
  • Publication number: 20130202646
    Abstract: In alternative embodiments, the invention provides cell-permeable recombinant or synthetic proteins to modulate autophagy, including a Tat-Atg5K130R (inhibitor of autophagy) and a Tat-Beclin 1 (stimulant or activator of autophagy), and nucleic acids expressing them and methods for making and using them, e.g., to treat conditions and disorders responsive to autophagy modulation (e.g., where autophagy is dysregulated), including neurodegeneration, cystic fibrosis, cancer, heart failure, diabetes, obesity, sarcopenia, aging, ischemia/reperfusion, inflammatory disorders including Crohns, ulcerative colitis, biliary cirrhosis, lysosomal storage diseases, infectious diseases associated with intracellular pathogens including viruses, bacteria, and parasites such as Trypanosomes and malaria.
    Type: Application
    Filed: February 25, 2011
    Publication date: August 8, 2013
    Applicant: SAN DIEGO STATE UNIVERSITY (SDSU) FOUNDATION
    Inventor: Roberta A Gottlieb
  • Publication number: 20130150283
    Abstract: This invention discloses isolated short peptides comprising the amino acid sequence Cys-Glu-Phe-His (CEFH; SEQ ID NOS: 1 and 15) and analogs thereof as well as compositions comprising CEFH peptides and analogs thereof. The CEFH peptides disclosed herein are effective in mediating the denitration of 3-nitrotyrosines (3-NT) in cellular proteins thereby preventing tissue damage associated with excess nitric oxide (NO) and its reactive species. The CEFH peptides disclosed herein are useful in the treatment of ischemia/reperfusion (I/R) injury and other disorders.
    Type: Application
    Filed: January 31, 2013
    Publication date: June 13, 2013
    Applicant: NEW YORK UNIVERSITY
    Inventor: New York University
  • Publication number: 20130109614
    Abstract: Enclosed is an antagonist, which includes a peptide chain represented by an amino acid sequence. The amino acid sequence has a short sequence, C-X1X2X3X4X5-N, which is situated before and neighbored to the third cysteine (Cys, C) of the N-terminus, wherein X1 is an amino acid with aromatic ring, hydrophobic property or long chain, and X2, X3, X4 and X5 are glutamine (G), serine (S), alanine (A) and proline (P) respectively. In one embodiment, X1 is phenylalanine (F). The present antagonists can be used to inhibit or treat with the diseases caused by the activated cells expressing CXCR1 and/or CXCR2 receptor, for example, the acute or chronic inflammatory reaction induced with polymorphonuclear neutrophils (PMNs) expressing CXCR1 and/or CXCR2 receptor, and angiogenesis accompanied by tumor growth inhibition.
    Type: Application
    Filed: June 12, 2012
    Publication date: May 2, 2013
    Inventors: Jya-Wei Cheng, Kuo-Chun Huang, Hsi-Tsung Cheng, Hui-Yuan Yu
  • Publication number: 20130053303
    Abstract: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.
    Type: Application
    Filed: October 5, 2012
    Publication date: February 28, 2013
    Applicant: Onyx Therapeutics, Inc.
    Inventor: Onyx Therapeutics, Inc.
  • Publication number: 20120295844
    Abstract: The present invention relates the use of aprotinin in the treatment of parasitic diseases or infections that affect domesticated mammals, in particular the cattle, especially bovines. In particular, aprotinin finds application in the fight against pathogenic effects induced by parasites in the Trypanosomatidae family, such as the protozoa that belong to the Trypanosoma genus or Leishmania genus. The invention also relates to the use of aprotinin for the prognosis of bovine tolerance to trypanosomosis infections.
    Type: Application
    Filed: January 21, 2011
    Publication date: November 22, 2012
    Applicant: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
    Inventors: David Berthier, Gerard Cuny, Sophie Thevenon, Isabelle Chantal, Anne Boissiere
  • Publication number: 20120295837
    Abstract: A novel class of antimicrobial polymeric agents, which include a plurality of amino acid residues, such as positively charged amino acid residues, and at least one hydrophobic residue linking therebetween, such as an omega-amino-fatty acid residue, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same.
    Type: Application
    Filed: December 8, 2011
    Publication date: November 22, 2012
    Applicant: Technion Research & Development Foundation Ltd.
    Inventors: Amram MOR, Inna RADZISHEVSKY
  • Publication number: 20120245082
    Abstract: NK-2 synthetic peptide derived from cationic core region of porcine NK-lysin has an antimicrobial and antitumor polypeptide that is considered to play a pivotal role in innate defense immunity. To evaluate the antimicrobial properties of synthetic chicken NK-lysin peptides, we investigated cytolytic activity against apicomplexan parasites like Eimeria sporozoites, Neospora tachyzoites and Cryptosporidum sporozoites. The chicken NK-2 (cNK-2) lytic peptide which corresponds to amino acid residues of porcine NK-2 peptide significantly disrupted Eimeria and Cryptosporidum sporozoites and Neospora tachyzoites. In contrast, no bactericidal activity was observed on E. coli BMH71-18. The cNK-2 lytic peptide is novel antimicrobial agent which can be used to intervene and treat economically costly infections in the animal industry.
    Type: Application
    Filed: March 24, 2011
    Publication date: September 27, 2012
    Inventors: Hyun Soon Lillehoj, Sung Hyen Lee, Yeong ho Hong
  • Publication number: 20120189682
    Abstract: The present invention relates to a product comprising at least two antibiofilm agents wherein at least one of the antibiofilm agents is an antimicrobial peptide. The second antibiofilm agent is generally a dispersant or an anti-adhesive agent. There is also provided the use of the product in the treatment of a microbial infection.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 26, 2012
    Applicant: Novabiotics Limited
    Inventors: Deborah O'Neil, Derry Mercer, Cedric Charrier
  • Patent number: 8221743
    Abstract: The present invention relates to the use of isolated polypeptides as coccidiostats and/or histomonastats. An example of a polypeptide of the invention is the so-called L12 protein from Bacillus licheniformis ATCC 14580.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: July 17, 2012
    Assignee: Novozymes A/S
    Inventors: Gilbert Weber, Jiri Broz
  • Publication number: 20120172292
    Abstract: This invention discloses a method for enhancing the efficacy of antimicrobial, anti-protozoa and anti-cancer treatments by co-administering an inhibitor of endogenous NO production and/or NO scavenger.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 5, 2012
    Applicant: NEW YORK UNIVERSITY
    Inventors: Evgeny A. Nudler, Ivan Gusarov
  • Publication number: 20120114679
    Abstract: The embodiments include methods of treating conditions requiring removal or destruction of cellular elements, such as benign or malignant tumors in humans, using compounds based on small peptides. The method includes, but is not limited to, administering the compounds intramuscularly, orally, intravenously, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier.
    Type: Application
    Filed: November 28, 2011
    Publication date: May 10, 2012
    Applicant: Nymox Pharmaceutical Corporation
    Inventors: Paul Averback, Jack Gemmell
  • Publication number: 20120108502
    Abstract: A novel structural class of highly N-methylated linear lipopeptide compounds useful for the treatment of parasitic disease.
    Type: Application
    Filed: March 20, 2010
    Publication date: May 3, 2012
    Applicant: The Regents of the University of California Office of Technology Transfer
    Inventors: Roger Linington, Laura Sanchez
  • Publication number: 20120088671
    Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
    Type: Application
    Filed: October 6, 2011
    Publication date: April 12, 2012
    Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS
    Inventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
  • Publication number: 20120070490
    Abstract: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides.
    Type: Application
    Filed: October 27, 2011
    Publication date: March 22, 2012
    Applicant: University of Georgia Research Foundation, Inc.
    Inventors: John M. Harrington, Stephen L. Hajduk
  • Publication number: 20120053117
    Abstract: The present invention relates to the use of serpentine receptors existent in parasites of genus Plasmodium for treating malaria.
    Type: Application
    Filed: October 2, 2009
    Publication date: March 1, 2012
    Applicants: Fundacao De Amparo A Pesquisa Do Estado De Sao Paulo- FAPESP, Universidade de Sao Paulo-USP
    Inventors: Célia Regina da Silva Garcia, Bettina Malnic, Luciana Madeira da Silva, Pedro Alexandre Favoretto Galante
  • Publication number: 20120039806
    Abstract: The present invention relates to the identification of proteins which bind the dendritic cell marker known as Clec9A. The present invention provides new compounds for targeting therapeutic agents such as antigens to dendritic cells. Also provided are methods of modulating a humoral and/or T cell mediated immune response to the antigen, methods of delivery of a cytotoxic agent to dendritic cells thereof involved in diseased states, methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, and methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof.
    Type: Application
    Filed: March 22, 2010
    Publication date: February 16, 2012
    Inventors: Mireille Hanna Lahoud, Irina Caminschi, Jian-Guo Zhang, Mark Francis Van Delft, David Ching Siang Huang, Nicos Anthony NIcola, Alan Cowman, Mark Dexter Wright
  • Publication number: 20120015870
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Application
    Filed: December 28, 2009
    Publication date: January 19, 2012
    Applicant: TEL HASHOMER MEDICAL RESEARCH, INFRASTRUCTURE AND SERVICES LTD.
    Inventor: Amir Zlotkin
  • Publication number: 20110294724
    Abstract: Disclosed is an antimicrobial peptide having an amino acid sequence of formula presented as (P1)M(nA1X1X2)N(P2)X, wherein P1 is selected from the group consisting of basic amino acids including Arg and Lys; A1 is selected from the group consisting of aromatic amino acids including Trp, Phe and Ala; X1 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; X2 is selected from the group consisting of basic amino acids or nonpolar amino acids, including Arg, Lys, Val, Leu, Ala and Ile; P2 is selected from the group consisting of basic amino acids including Arg and Lys; and the numbers of M and X are respectively 0˜2; when N>2, A1 is Ala and the Ala residues are less than N?2.
    Type: Application
    Filed: March 29, 2011
    Publication date: December 1, 2011
    Inventors: Jya-Wei CHENG, Kuo-Chun HUANG, His-Tsu CHENG, Hui-Yuan YU
  • Publication number: 20110280920
    Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of YDYNWY (SEQ ID NO: 1), YDYNLY (SEQ ID NO: 2), FDYNFY (SEQ ID NO: FDYNLY (SEQ ID NO: 4), FDYNWY (SEQ ID NO: 5), YDWNLY (SEQ ID NO: 6), YDWHLY (SEQ ID NO: 7) and WDYNLY (SEQ ID NO: 8), extracted from organisms such as aquatic organisms and mossor any other sequence described herein, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
    Type: Application
    Filed: September 23, 2009
    Publication date: November 17, 2011
    Inventors: Amir Zlotkin, Hen Kestenboim
  • Publication number: 20110257083
    Abstract: The invention relates to a merozoite surface protein 1 (“MSP-1”) preparation of Plasmodium falciparum, said MSP-1 preparation comprising a) a purified fragment p83/30 of the gp190/MSP-1 from Plasmodium without heterologous sequences, and b) a purified fragment p38/42 of the 190/MSP-1 from Plasmodium without heterologous sequences.
    Type: Application
    Filed: July 3, 2009
    Publication date: October 20, 2011
    Inventors: Hermann Bujard, Rolf Lutz, Christian Epp, Ute Wohlbier, Christian Kauth
  • Publication number: 20110256213
    Abstract: The invention generally relates to compositions and methods for the reduction or neutralization of toxins associated with a bacterial, mycobacterial, fungal, viral, or protozoal agent. More particularly, the invention is directed to sterically stabilized phospholipid micellar and liposomal compositions, which interact with the toxins to decrease or neutralize their toxicity. Additionally, the invention includes the use of sterically stabilized phospholipid micellar compositions comprising one or more water-insoluble antibiotic, antifungal, antiviral, antiprotozoal, or anti-inflammatory agent(s), wherein the micellar or liposomal composition inhibits the formation of aggregates. The invention further includes the use of sterically stabilized micelle and liposomal compositions to deliver compounds to the site of action, and in some cases targets the compound to the site of action, for the treatment of inflammation and infection.
    Type: Application
    Filed: October 15, 2009
    Publication date: October 20, 2011
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Hayat Onyuksel, Israel Rubinstein
  • Publication number: 20110171225
    Abstract: This invention provides reagents, methods and pharmaceutical compositions for treating and preventing malaria. Specifically, the invention provides methods for inhibiting a Plasmodium parasite, especially Plasmodium falciparum, from invading or replicating in a cell as well as vaccines for preventing malaria.
    Type: Application
    Filed: September 14, 2009
    Publication date: July 14, 2011
    Applicant: The Board of Trustees of the University of Illinois
    Inventors: Athar H. Chishti, Xuerong Li
  • Publication number: 20110152177
    Abstract: A feed composition comprising conventional feed ingredients, peptidoglycan and nucleotides is described. The feed composition can be used to prevent or reduce infectious diseases, and prevent symptoms related to an infectious disease in an animal. There is also provided a method for feeding of fish by providing this feed composition in the period previous of the challenge by an infection, during the infection or after the infection.
    Type: Application
    Filed: April 24, 2009
    Publication date: June 23, 2011
    Inventors: Jose Luis Vecino, Simon Wadsworth
  • Publication number: 20110150830
    Abstract: The invention relates to covalent conjugates between endoperoxides and small peptides and organic compounds that bind to molecular cavities on the transferrin or lactoferrin receptor, and the use of compositions comprising these conjugates to treat cancer, hyperproliferative disorders, inflammatory diseases, and infections.
    Type: Application
    Filed: February 14, 2011
    Publication date: June 23, 2011
    Applicant: WASHINGTON, UNIVERSITY OF
    Inventors: Tomikazu Sasaki, Henry Chiu-Yuen Lai, Narendra Pal Singh, Steve J. Oh
  • Publication number: 20110117107
    Abstract: Biomarkers for predicting the severity of malaria and methods for their detection are disclosed. In one aspect, the present application discloses CXCL4, CXCL10, VEGF, PGDF, IL-1Ra, IL-8, MIP-1?, sFas, Fas-L, sTNF-R2, and sTNF-R1 as biomarkers for the severity of malaria. In another aspect, the present application discloses a method for determining the severity of malaria and predicting mortality due to cerebral malaria. The method comprises the detection of the biomarkers CXCL4 and/or CXCL10 and at least one more biomarker and determining the severity of malaria and predicting mortality due to cerebral malaria based upon the ratio of expression of the biomarkers in the subject versus the expression of the biomarkers in a control.
    Type: Application
    Filed: December 2, 2010
    Publication date: May 19, 2011
    Applicant: MOREHOUSE SCHOOL OF MEDICINE
    Inventors: Jonathan K. Stiles, James W. Lillard, Henry B. Armatei Armah, Nana Otoo Wilson, Venkatachalam Udhayakumar
  • Publication number: 20110104064
    Abstract: Non-native synthetic peptide cyclized by means of a disulphide bridge, characterized by the amino acid sequence (E34P) that follows (SEQ ID No. 1): E-D-E-H-K-G-K-Y-C-R-L-G-N-D-C-R-T-T-E-P-T-T-T-A-T-P-R-G-T-P-T-P-A-P and a complex of non-native synthetic peptides that is intended to induce and characterize the prevention and/or treatment of conditions in mammals, the protective immunity of which depends on the stimulation of Th1 type lymphocytes, and, in particular, on a state of delayed hyperstimulation, containing: —said peptide (E34P), —the following sequence (A16E) of 16 amino acids (SEQ ID No. 2) or derivatives (structural analogues) thereof: A-A-R-C-A-R-C-R-E-G-Y-S-L-T-D-E —the following sequence (A16G) of 16 amino acids (SEQ ID No. 3) or derivatives (structural analogues) thereof: A-A-S-S-T-P-S-P-G-S-G-C-E-V-D-G, —and an adjuvant which preferably induces a cell-mediated response.
    Type: Application
    Filed: June 18, 2009
    Publication date: May 5, 2011
    Applicant: ORIDAN INC.
    Inventors: Serge Vicens, Grégory Hottin
  • Publication number: 20110105388
    Abstract: The present invention relates to the use of nifurtimox for the treatment of giardiosis, in particular in dogs and cats.
    Type: Application
    Filed: June 20, 2009
    Publication date: May 5, 2011
    Applicant: BAYER ANIMAL HEALTH GMBH
    Inventors: Gisela Greif, Achim Harder, Thomas Bach, Gabriele Petry, Eva-Maria Kruedewagen